Abstract:Rosai Dorfman disease (RDD) is a non-Langerhans cell histiocytic neoplasm characterized by sinus histiocytosis with variable emperipolesis. There is a limited understanding of the factors that contribute to disease progression. Traditional management of RDD consists of local therapies (resection, radiation) for localized disease and myelosuppression for systemic disease; targeted medications have also recently been introduced into clinical practice as an additional therapeutic modality. The goals of this study are to compare the impact of targeted therapies to conventional management of RDD and identify trends in laboratory data that may provide insight into disease progression. A retrospective analysis was conducted at a single institution over a 20-year period in 35 adult patients with histopathologic evidence of RDD without confounding secondary malignancies. Clinical data points included laboratory evaluation, molecular diagnostics, imaging, and therapies rendered. Binary data was utilized for statistical analysis and comparison of outcomes by treatment type and utilization of targeted agents. Evaluation of treatment response varied based on anatomic disease sites and baseline imaging modality. To standardize the radiographic analysis, we included PERCIST (if PET was utilized) or RECIST assessments (in the cases of CT or MR imaging). Conventional therapies rendered included local treatment (surgery, radiation, intralesional injections), systemic corticosteroids, immunotherapy, and chemotherapy while targeted agents included only small molecule inhibitors. In this analysis, primary disease was identified in cutaneous, osseous, and CNS structures (17, 11, and 6/35 patients respectively). Management consisted of surgery (12/35 patients), steroid and myelosuppressive therapies (9/35 each), immunotherapy (5/35), and targeted molecular agents (5/35). In evaluating outcomes, the proportion of partial responses was substantially higher in recipients of molecular as compared to conventional therapy (4/5 patients compared to 6/29) while complete responses were more common in the conventional therapy cohort (12/29 compared to 1/5). Lastly, an evaluation of peripheral blood absolute monocytes in all patients who had progressed on therapy identified a significant decrease in pre-progression values as compared to values following therapy re-institution (averages of 0.70 and 0.27 K/μL, respectively; p = 0.0002, 95% CI 0.652–0.2360). Larger-scale studies are needed to further evaluate the relevance of the monocyte trends that were identified in terms of their relationship to disease status. This study is the largest analysis of Rosai Dorfman disease, that we are aware of, from a single institution. In this cohort, the utilization of small molecule inhibitors corresponded to a greater increase in partial responses than conventional therapies, although the opposite effect has been observed in complete responses. This finding can be attributed to the recent introduction of targeted agents and shorter follow-up. We anticipate higher complete response rates with the use of small molecule in ongoing analyses over a longer follow-up period. The recognition of relative monocyte elevation prior to disease progression is an intriguing and to our knowledge, novel finding in the field of Rosai Dorfman disease. Future studies aimed at elucidating the implications of this trend are in progress.

MPN-421 A Case of Rosai-Dorfman Disease, Associated With KRAS 13C, POLE, and NDE1 Mutations, Masquerading as Chronic Myelomonocytic Leukemia: Complex Management Paradigm

Lenalidomide and dexamethasone for Rosai-Dorfman disease: a single arm, single center, prospective phase 2 study

[Primary intraosseous Rosai-Dorfman disease: a clinicopathological analysis of fourteen cases]

Single-cell analysis of a progressive Rosai–Dorfman disease affecting the cerebral parenchyma: a case report

Cutaneous Rosai-Dorfman disease with MAP2K1 mutation, initially mimicking an infection with parasitized histiocytes

Recurrent central nervous system Rosai-Dorfman disease with KRAS mutation: a case report

A rare case of facial cutaneous Rosai-Dorfman disease clinically mimicking basal cell carcinoma followed by multiple myeloma after 2 years

Primary Rosai‐Dorfman disease of the central nervous system: A clinical, histological, and molecular appraisal

Clinicopathological characteristics of extranodal Rosai-Dorfman disease: A retrospective case series of 25 patients

Rosai-Dorfman Disease in a Middle-Aged Man With Recurrent Pleural Effusions and Lymphadenopathy

Nodal and Extranodal Rosai-Dorfman Disease in Head and Neck: a Case Report with Literature Review

BRAF V600E mutation and high expression of PD-L1 in Rosai-Dorfman disease: case report and review of the literature

Rosai-Dorfman Disease Involving the Central Nervous System: Seven Cases from One Institute

Orbital Rosai-Dorfman Disease in a fifty-eight years old woman.

Rosai-Dorfman Disease of pancreas: rare aetiology mimicking malignancy

Investigating the correlation between small molecular inhibitor utilization, peripheral blood monocytes, and treatment outcomes in Rosai Dorfman disease

Clinical Features, Diagnosis, Treatment and Prognosis of Otolaryngological Extranodal Sinus Histiocytosis with Massive Lymphadenopathy (rosai–dorfman Disease, RDD)

Rosai-Dorfman Disease of the Lung with Features of Obliterative Arteritis

A Case Report of Rosai-Dorfman Disease in a 9-Year-old Girl with Left Tibia Involvement: Insights into Etiology, Clinical Presentation, and Treatment Advances

Review and a case of rare Rosai-Dorfman disease

Diagnosis and Treatment of Rosai-Dorfman Disease of the Spine: a Systematic Literature Review